(Q46013098)

18 December 2017

title

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. (English)

1 reference

18 December 2017

0 references

10

Patrick Hwu

1 reference

18 December 2017

author name string

Agop Y Bedikian

1

1 reference

18 December 2017

Nicholas E Papadopoulos

2

1 reference

18 December 2017

Kevin B Kim

3

1 reference

18 December 2017

Wen-Jen Hwu

4

1 reference

18 December 2017

Jade Homsi

5

1 reference

18 December 2017

Michelle R Glass

6

1 reference

18 December 2017

Suzanne Cain

7

1 reference

18 December 2017

Patrick Rudewicz

8

1 reference

18 December 2017

Laurent Vernillet

9

1 reference

18 December 2017

publication date

1 August 2009

1 reference

18 December 2017

published in

Cancer Investigation

1 reference

18 December 2017

volume

27

1 reference

18 December 2017

issue

7

1 reference

18 December 2017

page(s)

756-763

1 reference

18 December 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Pharmacological strategies to increase the antitumor activity of methylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Compressing drug development timelines in oncology using phase '0' trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802709159

10.1080/07357900802709159

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017